Leon G. Leanse
Abstract
With the rise in antimicrobial resistance, it is becoming increasingly difficult to successfully treat infections caused by an array of pathogens1. Over the past few years, antimicrobial blue light (aBL) has been emerging as an novel ‘drug-free’ approach to tackle multidrug-resistant (MDR) infections.